117 related articles for article (PubMed ID: 36300562)
21. Skeletal assessment in neuroblastoma--the pitfalls of iodine-123-MIBG scans.
Gordon I; Peters AM; Gutman A; Morony S; Dicks-Mireaux C; Pritchard J
J Nucl Med; 1990 Feb; 31(2):129-34. PubMed ID: 2313350
[TBL] [Abstract][Full Text] [Related]
22. 131I-MIBG in the diagnosis of primary and metastatic neuroblastoma.
El-Maghraby T
Gulf J Oncolog; 2007 Jul; (2):33-41. PubMed ID: 20084722
[TBL] [Abstract][Full Text] [Related]
23. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
Decarolis B; Schneider C; Hero B; Simon T; Volland R; Roels F; Dietlein M; Berthold F; Schmidt M
J Clin Oncol; 2013 Mar; 31(7):944-51. PubMed ID: 23341514
[TBL] [Abstract][Full Text] [Related]
24. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
25. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
Schmidt M; Simon T; Hero B; Schicha H; Berthold F
Eur J Cancer; 2008 Jul; 44(11):1552-8. PubMed ID: 18424129
[TBL] [Abstract][Full Text] [Related]
26. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.
Taggart DR; Han MM; Quach A; Groshen S; Ye W; Villablanca JG; Jackson HA; Mari Aparici C; Carlson D; Maris J; Hawkins R; Matthay KK
J Clin Oncol; 2009 Nov; 27(32):5343-9. PubMed ID: 19805691
[TBL] [Abstract][Full Text] [Related]
27. Immunoscintigraphic imaging of mIBG-negative metastases in neuroblastoma.
Berthold F; Waters W; Sieverts H; Linden A
Am J Pediatr Hematol Oncol; 1990; 12(1):61-2. PubMed ID: 2178460
[TBL] [Abstract][Full Text] [Related]
28. Residual meta-iodobenzyl guanidine (MIBG) positivity following therapy for metastatic neuroblastoma: Patient characteristics, imaging, and outcome.
Usmani N; Deyell RJ; Portwine C; Rafael MS; Moorehead PC; Shammas A; Vali R; Farfan M; Vanniyasingam T; Morgenstern DA; Irwin MS
Pediatr Blood Cancer; 2021 Dec; 68(12):e29289. PubMed ID: 34411405
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and treatment of neuroblastoma using metaiodobenzylguanidine.
Edeling CJ; Frederiksen PB; Kamper J; Jeppesen P
Clin Nucl Med; 1987 Aug; 12(8):632-7. PubMed ID: 3665302
[TBL] [Abstract][Full Text] [Related]
30. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.
Matthay KK; Edeline V; Lumbroso J; Tanguy ML; Asselain B; Zucker JM; Valteau-Couanet D; Hartmann O; Michon J
J Clin Oncol; 2003 Jul; 21(13):2486-91. PubMed ID: 12829667
[TBL] [Abstract][Full Text] [Related]
31. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma.
Shulkin BL; Shapiro B; Hutchinson RJ
J Nucl Med; 1992 Oct; 33(10):1735-40. PubMed ID: 1403138
[TBL] [Abstract][Full Text] [Related]
32. The clinical use of 131I-meta-iodo-benzylguanidine (MIBG) for the diagnosis of neuroblastoma.
Zagar I; Mitrović S; Adanja G; Maksimović L; Ivanovski P; Han R; Kovacić K
Med Pregl; 1993; 46 Suppl 1():74-5. PubMed ID: 8569615
[TBL] [Abstract][Full Text] [Related]
33. [131I]metaiodobenzylguanidine in neuroblastoma patients at diagnosis.
Mastrangelo R; Lasorella A; Troncone L; Rufini V; Iavarone A; Riccardi R
J Nucl Biol Med (1991); 1991; 35(4):252-4. PubMed ID: 1823829
[TBL] [Abstract][Full Text] [Related]
34. [Value of 123I-MIBG scanning, neuron-specific enolase and serum ferritin in the diagnosis and follow-up of patients with neuroblastoma].
Hervás Benito I; Rivas Sánchez A; Bello Arques P; Cañete A; Fernández JM; Saura Quiles A; González Cabezas P; Ruiz Rodríguez JC; Castell V; Pérez Pastor JL; Monfort JA; Mateo Navarro A
Rev Esp Med Nucl; 2001 Aug; 20(5):369-76. PubMed ID: 11470071
[TBL] [Abstract][Full Text] [Related]
35. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
DuBois SG; Mody R; Naranjo A; Van Ryn C; Russ D; Oldridge D; Kreissman S; Baker DL; Parisi M; Shulkin BL; Bai H; Diskin SJ; Batra V; Maris JM; Park JR; Matthay KK; Yanik G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28383813
[TBL] [Abstract][Full Text] [Related]
36. Neuroblastoma: dose-related sensitivity of MIBG scanning in detection.
Parisi MT; Matthay KK; Huberty JP; Hattner RS
Radiology; 1992 Aug; 184(2):463-7. PubMed ID: 1620849
[TBL] [Abstract][Full Text] [Related]
37.
Gassenmaier S; Bares R; Barreuther M; Flaadt T; Lang P; Schaefer JF; Tsiflikas I
Pediatr Radiol; 2021 Jun; 51(7):1223-1230. PubMed ID: 33544193
[TBL] [Abstract][Full Text] [Related]
38. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the utility of
Gauguet JM; Pace-Emerson T; Grant FD; Shusterman S; DuBois SG; Frazier AL; Voss SD
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449267
[TBL] [Abstract][Full Text] [Related]
40. Positive MIBG scanning at the time of relapse in neuroblastoma which was MIBG negative at diagnosis.
Schwarz KB; Driver I; Lewis IJ; Taylor RE
Br J Radiol; 1997 Jan; 70():90-2. PubMed ID: 9059302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
